ADDED
On June 30, 2025, we entered into a Business Combination Agreement (the Business Combination Agreement ) with DRC Medicine Inc., DRC Medicine Ltd.
and DRC Merger Inc., as disclosed in our Current Report on Form 8-K filed on July 1, 2025.
Accordingly, we are no longer pursuing other prospective target businesses and are focused on completing the proposed business combination.
We will not undertake our initial business combination with any company being based in or having the majority of the company s operations in Greater China other than pursuant to the Business Combination Agreement described above.
On June 30, 2025, we entered into a Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd.
and DRC Merger Inc., as disclosed in our Current Report on Form 8-K filed on July 1, 2025, and we are currently focused on completing the proposed business combination.
We believe that, through their broad range of industry contacts and deep industry insights, we have been able to identify and access, and will continue to evaluate, a differentiated pipeline of high-quality business combination opportunities.
Following the execution of the Business Combination Agreement described above, we are currently focused on completing the proposed business combination.
Strong understanding of the public and private markets We believe that the significant experience of our management team in biotechnology, capital markets and M A transactions has been instrumental in identifying and evaluating potential business combination opportunities, including the proposed business combination described above, and will continue to support us in consummating such transaction.
We are currently focused on executing the proposed business combination and believe that our experience in structuring and negotiating transactions will support the successful completion of such transaction.
REMOVED
We do not have any specific business combination under consideration and we have not (nor has anyone on our behalf), directly or indirectly, contacted any prospective target business or had any substantive discussions, formal or otherwise, with respect to such a transaction.
We will not undertake our initial business combination with any company being based in or having the majority of the company s operations in Greater China.
We believe that our management s track record of identifying and sourcing business combination targets positions us well to appropriately evaluate potential candidates and select the one that will be well received by the public markets 2 Differentiated access to deal sourcing and leading industry relationships Our target identification and selection process will leverage the broad and deep relationship network of our management team, sponsor and other strategic and operating partners across corporate executives, founders, venture capitalists and private equity firms.
We believe that, through their broad range of industry contacts and deep industry insights, we are well-positioned to identify and access a differentiated pipeline of high-quality business combination opportunities.
Strong understanding of the public and private markets We believe that the significant experience of our management team in biotechnology, capital markets and M A transactions will greatly assist us in consummating transactions at attractive valuations.
We believe that by focusing our investment activities on these types of transactions, we are able to generate investment opportunities that have attractive risk/reward profiles based on their valuations and structural characteristics.
We will not undertake our initial business combination with any company being based in or having the majority of the company s operations in Greater China.
We have identified the following general criteria and guidelines, which we believe are important in evaluating prospective target businesses.
We will have until 12 months from the closing of this offering to consummate an initial business combination.
Financial Position With funds available for a business combination initially in the amount of $50,000,000 assuming no redemptions before fees and expenses associated with our initial business combination, we offer a target business a variety of options such as creating a liquidity event for its owners, providing capital for the potential growth and expansion of its operations or strengthening its balance sheet by reducing its debt ratio.